

Senate Community Affairs Committee

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH PORTFOLIO

Budget Estimates 2017 - 2018, 29 & 30 May 2017

Ref No: SQ17-000753

OUTCOME: 4 – Individual Health Benefits

Topic: Life Saving Drugs Program

Type of Question: Written Question on Notice

Senator: Watt, Murray

Question:

There are a number of treatments currently going through the LSDP process. How many of these treatments are there and where are they currently up to in the process?

Answer:

Two.

Elosulfase alfa (Vimizim[®]) has been approved for inclusion on the Life Saving Drugs Program (LSDP) for the treatment of mucopolysaccharidosis (MPS) IVA, with effect from 1 August 2017.

An application to list an additional product, eliglustat (Cerdelga[®]), on the LSDP for the treatment of Gaucher disease type 1 is currently being considered.